Gerald U. Denk, Carol J. Soroka, Albert Mennone, Hermann Koepsell, Ulrich Beuers, James L. Boyer – 26 April 2004 – The liver plays a major role in biotransformation and elimination of various therapeutic agents and xenobiotics, many of which are organic cations and substrates of the organic cation transporter 1 (Oct1, Slc22a1). Oct1 is expressed at the basolateral membranes of hepatocytes and proximal renal tubules. Although Oct1 is the major uptake mechanism in hepatocytes for many pharmaceutical compounds, little is known about the effects of liver injury on this process.

Ignazio Grattagliano, Stefan Russmann, Vincenzo O. Palmieri, Peter Jüni, Florian Bihl, Piero Portincasa, Giuseppe Palasciano, Bernhard H. Lauterburg – 26 April 2004 – Hemolysis is a frequent adverse effect of ribavirin (RBV). It has been suggested that oxidative stress plays a role, but mechanisms and predictive risk factors for severe forms remain unknown.

26 April 2004

Nora V. Bergasa – 26 April 2004

Sándor Paku, Peter Nagy, László Kopper, Snorri S. Thorgeirsson – 26 April 2004 – The 2‐acetylaminofluorene (AAF)/partial hepatectomy (PH) model is one of the most extensively studied experimental systems for oval cell proliferation and differentiation. We have previously described the oval cells as forming ductular structures surrounded by basement membrane, representing extensions of the canals of Hering. Herein we analyze the differentiation of oval cells into hepatocytes after varying degrees of liver damage induced by AAF.

Igor M. Sauer, Max Goetz, Ingo Steffen, Gesa Walter, Daniel C. Kehr, Ruth Schwartlander, Yoon J. Hwang, Andreas Pascher, Joerg C. Gerlach, Peter Neuhaus – 26 April 2004 – The detoxification capacities of single‐pass albumin dialysis (SPAD), the molecular adsorbents recirculation system, (MARS) and continuous veno‐venous hemodiafiltration (CVVHDF) were compared in vitro. In each experiment 4,100 mL of toxin‐loaded human plasma was processed for 6.5 hours. MARS treatment (n = 6) was undertaken in combination with CVVHDF.

Neil Kaplowitz – 26 April 2004

Meagan J. Walsh, Daina M. Vanags, Andrew D. Clouston, Michelle M. Richardson, David M. Purdie, Julie R. Jonsson, Elizabeth E. Powell – 26 April 2004 – Steatosis is increasingly recognized as a cofactor influencing the progression of fibrosis in chronic hepatitis C; however, the mechanisms by which it contributes to liver injury remain uncertain.

Christopher E. P. Goldring, Neil R. Kitteringham, Robert Elsby, Laura E. Randle, Yuri N. Clement, Dominic P. Williams, Michael McMahon, John D. Hayes, Ken Itoh, Masayuki Yamamoto, B. Kevin Park – 26 April 2004 – The transcription factor NF‐E2‐related factor 2 (Nrf2) plays an essential role in the mammalian response to chemical and oxidative stress through induction of hepatic phase II detoxification enzymes and regulation of glutathione (GSH).

Jesús Medina, Alicia G. Arroyo, Francisco Sánchez‐Madrid, Ricardo Moreno‐Otero – 26 April 2004 – Intrahepatic hypoxia may occur during the inflammatory and fibrotic processes that characterize several chronic liver diseases of viral and autoimmune origin. As a consequence, new vascular structures are formed to provide oxygen and nutrients. Angiogenesis involves a tightly regulated network of cellular and molecular mechanisms that result in the formation of functional vessels.